Modality
Vaccine
MOA
PD-1i
Target
CGRP
Pathway
Sphingolipid
Urothelial CaACCIgAN
Development Pipeline
Preclinical
~Oct 2014
→ ~Jan 2016
Phase 1
~Apr 2016
→ ~Jul 2017
Phase 2
Oct 2017
→ Jan 2026
Phase 2Current
NCT08348829
692 pts·IgAN
2017-10→2026-01·Recruiting
692 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-083mo agoPh2 Data· IgAN
Trial Timeline
Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2
Recruit…
Catalysts
Ph2 Data
2026-01-08 · 3mo ago
IgAN
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08348829 | Phase 2 | IgAN | Recruiting | 692 | DAS28 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| TAK-9344 | Takeda | Phase 3 | CGRP | |
| Nirabrutinib | BioNTech | Phase 2/3 | CDK2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| BII-4342 | Biogen | Phase 2/3 | CGRP | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 | |
| LEG-9870 | Legend Biotech | Phase 1 | CGRP | |
| ASN-4879 | Ascendis Pharma | Phase 3 | CGRP | |
| MDG-611 | Madrigal Pharma | Approved | CGRP |